top of page

Mallinckrodt’s muscular dystrophy drug receives FDA fast track designation

The US Food and Drug Administration (FDA) has granted Mallinckrodt’s request for a fast track designation for synacthen depot for the treatment of Duchenne muscular dystrophy (DMD).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page